Alnylam Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $426.52, Implies 49% Upside

• According to estimates from 23 analysts, Alnylam Pharmaceuticals, Inc. stock's average price target has fallen from $437.22 to $426.52, with forecasts ranging from $285 to $536 per share
• Based on the Jul. 29 closing price, the updated target implies approximately 49% potential upside
• Consensus rating remains at “Buy” across 30 covering analysts, with 22 Buys, 8 Holds and 0 Sells

Explore more price target data and ratings for Alnylam Pharmaceuticals, Inc. on the , and track all previous and future analyst recommendations for Alnylam Pharmaceuticals, Inc. in the dedicated .

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.